Li et al., found that circNDUFB2 acts as an antitumor immune modulator via destabilizing IGF2BPs and activating RIG-I-MAVS signaling to facilitate the recruitment of immune cells in non-small-cell lung cancer (NSCLC) [145]. Here, RIGI is linked to non-small cell lung carcinoma.